Germany · Delayed Price · Currency is EUR Vicore Pharma Holding AB Statistics
Total Valuation
FRA:6Y4 has a market cap or net worth of EUR 253.39 million. The enterprise value is 177.24 million.
| Market Cap | 253.39M |
| Enterprise Value | 177.24M |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 281.53M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +104.85% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 6.32% |
| Owned by Institutions (%) | 27.55% |
| Float | 200.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 329.53 |
| PB Ratio | 3.51 |
| P/TBV Ratio | 3.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.62 |
| EV / Sales | 228.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.86
| Current Ratio | 13.86 |
| Quick Ratio | 13.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.22 |
Financial Efficiency
Return on equity (ROE) is -72.16% and return on invested capital (ROIC) is -43.91%.
| Return on Equity (ROE) | -72.16% |
| Return on Assets (ROA) | -40.56% |
| Return on Invested Capital (ROIC) | -43.91% |
| Return on Capital Employed (ROCE) | -51.38% |
| Revenue Per Employee | 21,359 |
| Profits Per Employee | -1.07M |
| Employee Count | 29 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +50.96% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +50.96% |
| 50-Day Moving Average | 1.00 |
| 200-Day Moving Average | 0.82 |
| Relative Strength Index (RSI) | 50.60 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:6Y4 had revenue of EUR 768,922 and -38.39 million in losses. Loss per share was -0.17.
| Revenue | 768,922 |
| Gross Profit | 768,922 |
| Operating Income | -37.38M |
| Pretax Income | -38.39M |
| Net Income | -38.39M |
| EBITDA | -37.22M |
| EBIT | -37.38M |
| Loss Per Share | -0.17 |
Balance Sheet
The company has 75.60 million in cash and n/a in debt, giving a net cash position of 75.60 million.
| Cash & Cash Equivalents | 75.60M |
| Total Debt | n/a |
| Net Cash | 75.60M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 72.24M |
| Book Value Per Share | 0.31 |
| Working Capital | 72.62M |
Cash Flow
| Operating Cash Flow | -31.13M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -4,860.85% |
| Pretax Margin | -4,992.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:6Y4 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -104.85% |
| Shareholder Yield | -104.85% |
| Earnings Yield | -15.15% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |